Literature DB >> 11689688

Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome.

R E Kiernan1, S Emiliani, K Nakayama, A Castro, J C Labbé, T Lorca, K Nakayama Ki, M Benkirane.   

Abstract

CDK9 paired with cyclin T1 forms the human P-TEFb complex and stimulates productive transcription through phosphorylation of the RNA polymerase II C-terminal domain. Here we report that CDK9 is ubiquitinated and degraded by the proteasome whereas cyclin T1 is stable. SCF(SKP2) was recruited to CDK9/cyclin T1 via cyclin T1 in an interaction requiring its PEST domain. CDK9 ubiquitination was modulated by cyclin T1 and p45(SKP2). CDK9 accumulated in p45(SKP2-/-) cells, and its expression during the cell cycle was periodic. The transcriptional activity of CDK9/cyclin T1 on the class II major histocompatibility complex promoter could be regulated by CDK9 degradation in vivo. We propose a novel mechanism whereby recruitment of SCF(SKP2) is mediated by cyclin T1 while ubiquitination occurs exclusively on CDK9.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689688      PMCID: PMC99964          DOI: 10.1128/MCB.21.23.7956-7970.2001

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  52 in total

Review 1.  Interplay between positive and negative elongation factors: drawing a new view of DRB.

Authors:  Y Yamaguchi; T Wada; H Handa
Journal:  Genes Cells       Date:  1998-01       Impact factor: 1.891

Review 2.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

3.  PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo.

Authors:  M O Gold; X Yang; C H Herrmann; A P Rice
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Identification of multiple cyclin subunits of human P-TEFb.

Authors:  J Peng; Y Zhu; J T Milton; D H Price
Journal:  Genes Dev       Date:  1998-03-01       Impact factor: 11.361

Review 5.  Proteolysis and the G1-S transition: the SCF connection.

Authors:  W Krek
Journal:  Curr Opin Genet Dev       Date:  1998-02       Impact factor: 5.578

6.  Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat.

Authors:  M Benkirane; R F Chun; H Xiao; V V Ogryzko; B H Howard; Y Nakatani; K T Jeang
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

7.  The DMB promoter: delineation, in vivo footprint, trans-activation, and trans-dominant suppression.

Authors:  J P Ting; K L Wright; K C Chin; W J Brickey; G Li
Journal:  J Immunol       Date:  1997-12-01       Impact factor: 5.422

8.  TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines.

Authors:  X Yang; M O Gold; D N Tang; D E Lewis; E Aguilar-Cordova; A P Rice; C H Herrmann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

9.  Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway.

Authors:  J Lisztwan; A Marti; H Sutterlüty; M Gstaiger; C Wirbelauer; W Krek
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

10.  A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif.

Authors:  F Margottin; S P Bour; H Durand; L Selig; S Benichou; V Richard; D Thomas; K Strebel; R Benarous
Journal:  Mol Cell       Date:  1998-03       Impact factor: 17.970

View more
  41 in total

Review 1.  RNA polymerase II elongation control.

Authors:  Qiang Zhou; Tiandao Li; David H Price
Journal:  Annu Rev Biochem       Date:  2012-03-09       Impact factor: 23.643

2.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

3.  Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.

Authors:  Kazuhiro Maki; Fusako Sugita; Yuka Nakamura; Ko Sasaki; Kinuko Mitani
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

Review 4.  CYCLINg through transcription: posttranslational modifications of P-TEFb regulate transcription elongation.

Authors:  Sungyoo Cho; Sebastian Schroeder; Melanie Ott
Journal:  Cell Cycle       Date:  2010-05-29       Impact factor: 4.534

5.  Ubiquitylation of Cdk9 by Skp2 facilitates optimal Tat transactivation.

Authors:  Matjaz Barboric; Fan Zhang; Mojca Besenicar; Ana Plemenitas; B Matija Peterlin
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner.

Authors:  Annemieke A Michels; Van Trung Nguyen; Alessandro Fraldi; Valérie Labas; Mia Edwards; François Bonnet; Luigi Lania; Olivier Bensaude
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

7.  Human immunodeficiency virus type 1 infection induces cyclin T1 expression in macrophages.

Authors:  Li-Ying Liou; Christine H Herrmann; Andrew P Rice
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2.

Authors:  Judit Garriga; Sabyasachi Bhattacharya; Joaquim Calbó; Renée M Marshall; May Truongcao; Dale S Haines; Xavier Graña
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

9.  Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.

Authors:  Guoxiong Xu; Stefanie Bernaudo; Guodong Fu; Daniel Y Lee; Burton B Yang; Chun Peng
Journal:  Mol Biol Cell       Date:  2008-09-10       Impact factor: 4.138

10.  P-TEFb- the final frontier.

Authors:  Jiri Kohoutek
Journal:  Cell Div       Date:  2009-09-02       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.